Bradley A. McGregor, MD
Combination therapies have become a standard of care in advanced renal cell carcinoma (RCC) in the United States following the FDA approval of nivolumab (Opdivo) and ipilimumab (Yervoy) as a frontline treatment for patients with intermediate- and poor-risk disease. Bradley McGregor, MD, explained that combination therapies are now poised to have a global impact.
“As we look toward the future of RCC, combination therapy, particularly in the frontline setting, is going to become a new standard of care around the world,” said McGregor, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of Medicine, Harvard Medical School.
... to read the full story